{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:56:25Z","timestamp":1776707785614,"version":"3.51.2"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.critrevonc.2024.104388","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T01:55:50Z","timestamp":1715738150000},"page":"104388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6334-4079","authenticated-orcid":false,"given":"Tarik","family":"Demir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Moloney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devalingam","family":"Mahalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104388_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108344","article-title":"RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives","volume":"242","author":"Addeo","year":"2023","journal-title":"Pharm. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MOG.0b013e3283523c7e","article-title":"Genetic profiling of intrahepatic cholangiocarcinoma","volume":"28","author":"Andersen","year":"2012","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104388_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.41165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"Supplement_1","key":"10.1016\/j.critrevonc.2024.104388_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/GO.2023.9.Supplement_1.33","article-title":"A comprehensive survey of tumor mutation burden (TMB) using the AACR GENIE cbioportal database: Pathogenesis of NTRK and RET fusion (NTRK+\/RET+) positive colorectal (CRC)","volume":"9","author":"Arter","year":"2023","journal-title":"JCO Glob. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092628","article-title":"The Role of HER2 Status in the Biliary Tract Cancers","volume":"15","author":"Ayasun","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104388_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12_Supplement_1","key":"10.1016\/j.critrevonc.2024.104388_bib10","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.ADVPRECMED20-09","article-title":"Cancers with NTRK gene fusions: molecular characteristics and prognosis","volume":"26","author":"Bazhenova","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11523-021-00815-4","article-title":"TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting","volume":"16","author":"Bazhenova","year":"2021","journal-title":"Target Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines(R) Insights: Biliary Tract Cancers, Version 2.2023.","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, Version 2.2023: Featured Updates to the NCCN Guidelines.","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"21","key":"10.1016\/j.critrevonc.2024.104388_bib14","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence","volume":"20","author":"de Biasi","year":"2014","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.critrevonc.2024.104388_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-018-0064-z","article-title":"Emerging role of precision medicine in biliary tract cancers","volume":"2","author":"Bogenberger","year":"2018","journal-title":"NPJ Precis Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4009","article-title":"Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors","volume":"41","author":"Borad","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2024.104388_bib19","doi-asserted-by":"crossref","first-page":"1137510","DOI":"10.3389\/fonc.2023.1137510","article-title":"Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue","volume":"13","author":"Brandi","year":"2023","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib20","first-page":"1915","article-title":"Expression of GLS1 in intrahepatic cholangiocarcinoma and its clinical significance","volume":"20","author":"Cao","year":"2019","journal-title":"Mol. Med Rep."},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104388_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164026","article-title":"BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104388_bib22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat. Genet"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40659-015-0016-9","article-title":"TGF-\u03b21 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma","volume":"48","author":"Chen","year":"2015","journal-title":"Biol. Res"},{"key":"10.1016\/j.critrevonc.2024.104388_bib24","doi-asserted-by":"crossref","first-page":"25369","DOI":"10.1038\/srep25369","article-title":"Expression levels of ROS1\/ALK\/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer","volume":"6","author":"Chiang","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104388_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41379-019-0417-3","article-title":"NTRK gene rearrangements are highly enriched in MLH1\/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases","volume":"33","author":"Chou","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658097","article-title":"Dickkopf-1: A Promising Target for Cancer Immunotherapy","volume":"12","author":"Chu","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ctrv.2018.11.001","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives","volume":"72","author":"Corti","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"7274","key":"10.1016\/j.critrevonc.2024.104388_bib29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib30","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib31","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00432-022-03983-6","article-title":"A phase 1 study of IDH305 in patients with IDH1(R132)-mutant acute myeloid leukemia or myelodysplastic syndrome.","volume":"149","author":"DiNardo","year":"2023","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104388_bib33","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104388_bib35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning Cold into Hot: Firing up the Tumor Microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2024.104388_bib37","series-title":"IMbrave151: A phase 2, randomized, double-blind, placebo-controlled study of atezolizumab with or without bevacizumab in combination with cisplatin plus gemcitabine in patients with untreated, advanced biliary tract cancer","author":"El-Khoueiry","year":"2023"},{"issue":"4_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.347","article-title":"Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA)","volume":"41","author":"Elimova","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib40","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1158\/2767-9764.CRC-22-0436","article-title":"Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma","volume":"3","author":"Fanucci","year":"2023","journal-title":"Cancer Res Commun."},{"key":"10.1016\/j.critrevonc.2024.104388_bib41","series-title":"ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC)","author":"Fan","year":"2024"},{"key":"10.1016\/j.critrevonc.2024.104388_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104224","article-title":"Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts' position paper","volume":"194","author":"Fassan","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib43","unstructured":"FDA Approves First Targeted Treatment for Patients with Cholangiocarcinoma, a Cancer of Bile Ducts. \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts\u3009 (Accessed on April 21, 2020)."},{"issue":"4_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.430","article-title":"Updated analysis with longer follow up of a phase 2a study evaluating erdafitinib in Asian patients (pts) with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) alterations","volume":"40","author":"Feng","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104388_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cells12162098","article-title":"Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis","volume":"12","author":"Frega","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2017","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2013.206","article-title":"BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma","volume":"27","author":"Goeppert","year":"2014","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib48","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/2159-8290.CD-22-1377","article-title":"N-of-1 trials in cancer drug development","volume":"13","author":"Gouda","year":"2023","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib49","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2024.104388_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib51","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104388_bib52","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1158\/1078-0432.CCR-20-1310","article-title":"Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine\/Cisplatin in Advanced Biliary Tract Cancer","volume":"26","author":"Goyal","year":"2020","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015640","article-title":"Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma","volume":"6","author":"Gu","year":"2011","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104388_bib54","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","article-title":"HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2","volume":"23","author":"Hanker","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib55","article-title":"Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT \u2018basket\u2019trial","volume":"40","author":"Harding","year":"2022","journal-title":"Change"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104388_bib56","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib58","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1053\/j.gastro.2021.01.028","article-title":"Axin2(+) Peribiliary Glands in the Periampullary Region Generate Biliary Epithelial Stem Cells That Give Rise to Ampullary Carcinoma.","volume":"160","author":"Hayata","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2024.104388_bib59","series-title":"ETCTN 10476: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer","author":"Heumann","year":"2023"},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib60","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3141","article-title":"Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer","volume":"41","author":"Hong","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104388_bib61","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib62","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3390\/cancers12061666","article-title":"Combined therapy with anti-PD1 and BRAF and\/or MEK inhibitor for advanced melanoma: A multicenter cohort study","volume":"12","author":"Huynh","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11684-023-0985-y","article-title":"Progress and challenges in RET-targeted cancer therapy","volume":"17","author":"Hu","year":"2023","journal-title":"Front Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","article-title":"Cholangiocarcinoma - novel biological insights and therapeutic strategies","volume":"20","author":"Ilyas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104388_bib66","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: Utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104388_bib67","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.427","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01","volume":"40","author":"Javle","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib69","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib70","series-title":"Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial","author":"Javle","year":"2024"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020161","article-title":"Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin","volume":"13","author":"Jeong","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104388_bib72","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat. Genet"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib73","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib74","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e16643","article-title":"A phase Ib\/II study of olutasidenib in patients with relapsed\/refractory IDH1 mutant solid tumors: safety and efficacy as single agent","volume":"38","author":"Jones","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib75","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.541","article-title":"PD-L1 as a predictor of chemo-immunotherapy response in biliary tract cancers: a systematic review and meta-analysis","volume":"42","author":"Juarez","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib76","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104388_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153993","article-title":"New era of immune-based therapy in intrahepatic cholangiocarcinoma","volume":"15","author":"Kawamura","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104388_bib79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: first global approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"issue":"10391","key":"10.1016\/j.critrevonc.2024.104388_bib80","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2024.104388_bib81","article-title":"HER2 Aberrations as a novel marker in advanced biliary tract Cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104388_bib82","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104388_bib83","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1002\/cncr.32964","article-title":"A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer","volume":"126","author":"Kim","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib84","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib85","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a Phase 2 nonrandomized clinical trial","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104388_bib86","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib87","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1186\/s12885-022-10286-z","article-title":"Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015","volume":"22","author":"Koshiol","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib88","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104388_bib89","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3099","article-title":"Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced\/metastatic NTRK fusion-positive (NTRK-fp) solid tumors","volume":"40","author":"Krzakowski","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102627","article-title":"Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma","volume":"121","author":"Lamarca","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib92","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: Ready for \"prime time\" in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104388_bib93","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jclinpath-2015-203394","article-title":"Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets","volume":"69","author":"Lee","year":"2016","journal-title":"J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib94","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104388_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174229","article-title":"Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: a multicenter open-label phase 1\/2a Trial","volume":"14","author":"Leem","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6349","key":"10.1016\/j.critrevonc.2024.104388_bib96","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib97","article-title":"BRAF mutation in Chinese biliary tract cancer patients","volume":"38","author":"Li","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104388_bib99","article-title":"FGFR families: biological functions and therapeutic interventions in tumors","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm (2020)"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104388_bib101","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1016\/j.annonc.2022.07.093","article-title":"65P A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers","volume":"33","author":"Li","year":"2022","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104388_bib102","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib103","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104388_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133312","article-title":"Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies","volume":"15","author":"Lo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081141","article-title":"Impact of Aberrant \u03b2-Catenin Pathway on Cholangiocarcinoma Heterogeneity","volume":"12","author":"Lozano","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183932","article-title":"TGF-\u03b2 signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: a study on human primary cell cultures","volume":"12","author":"Lustri","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2024.104388_bib107","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","article-title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","volume":"31","author":"Lwin","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study.","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104388_bib109","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10585-022-10189-0","article-title":"Resistance to targeted therapies in acute myeloid leukemia","volume":"40","author":"Mecklenbrauck","year":"2023","journal-title":"Clin. Exp. Metastas-.-."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib111","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104388_bib113","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/1078-0432.CCR-23-0036","article-title":"Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: preclinical evaluation and phase ib multicenter clinical trial (BilT-04)","volume":"29","author":"Mohan","year":"2023","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib114","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"issue":"36","key":"10.1016\/j.critrevonc.2024.104388_bib116","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib117","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib118","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4006","article-title":"Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)","volume":"40","author":"Ohba","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib119","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.439","article-title":"Varlitinib in combination with gemcitabine and cisplatin for treatment-na\u00efve advanced biliary tract cancer","volume":"40","author":"Oh","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.4097","article-title":"Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial","volume":"41","author":"Ohba","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib121","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib122","article-title":"Analysis of NTRK Alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104388_bib123","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/annonc\/mdu157","article-title":"A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors","volume":"25","author":"Pant","year":"2014","journal-title":"Ann. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib124","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3098","article-title":"A phase 1, multicenter, open-label study of a new BRAF inhibitor ABM-1310 in adult patients (pts) with BRAFv600-mutated solid tumors","volume":"41","author":"Piha-Paul","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib125","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib126","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S2468-1253(23)00147-4","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice","volume":"8","author":"Pinter","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib127","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jamaoncol.2017.4182","article-title":"Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers","volume":"4","author":"Prasad","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104388_bib128","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23062916","article-title":"The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer","volume":"23","author":"Qin","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104388_bib130","article-title":"Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat. Res Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8_Supplement","key":"10.1016\/j.critrevonc.2024.104388_bib132","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT098","article-title":"Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors","volume":"83","author":"Rodon","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib133","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.critrevonc.2024.104388_bib134","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/cncr.34394","article-title":"A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01","volume":"128","author":"Sahai","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104388_bib135","series-title":"Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02","author":"Sahai","year":"2023"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104388_bib136","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2021.1867537","article-title":"Regorafenib, an investigational agent for the treatment of cholangiocarcinoma","volume":"30","author":"Sahin","year":"2021","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"33","key":"10.1016\/j.critrevonc.2024.104388_bib137","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in Patients With Tumors With BRAF(V600E) Mutations: Results of the NCI-MATCH Trial Subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104388_bib138","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT022","article-title":"CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden","author":"Schenker","year":"2022","journal-title":"CANCER Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104388_bib139","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib140","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/cpt.2953","article-title":"Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework","volume":"114","author":"Shemesh","year":"2023","journal-title":"Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib141","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","article-title":"Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study","volume":"8","author":"Shi","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib142","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib143","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib144","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib145","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2024.104388_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102649","article-title":"Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing","volume":"122","author":"Stenzinger","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104388_bib147","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104388_bib148","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib149","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2024.104388_bib150","article-title":"Revolutionizing cancer drug development: Harnessing the potential of basket trials","author":"Subbiah","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104388_bib151","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep. Med."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104388_bib152","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.6614","article-title":"An application of extrapolating clinical data from single-arm trials to assess comparative effectiveness","volume":"41","author":"Suh","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib153","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104388_bib154","unstructured":"Tafinlar (dabrafenib) capsules, prescribing information. US Food and Drug Administration. Available at: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/202806Orig1s022ltr.pdf\u3009 (Accessed on June 29, 2022)."},{"issue":"18 Pt 1","key":"10.1016\/j.critrevonc.2024.104388_bib155","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1158\/1078-0432.CCR-04-0579","article-title":"Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis","volume":"10","author":"Takahashi","year":"2004","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104388_bib156","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-020-07365-4","article-title":"Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results","volume":"20","author":"Ueno","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2024.104388_bib157","unstructured":"US FDA approval letter for ivosidenib in advanced cholangiocarcinoma. Available at: \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/211192Orig1s008ltr.pdf\u3009 (Accessed on August 30, 2021)."},{"key":"10.1016\/j.critrevonc.2024.104388_bib158","unstructured":"US Food and Drug Administration (FDA) Label for Larotrectinib \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211710s000lbl.pdf?et_cid=40674858&et_rid=931330620&linkid=https%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2018%2f211710s000lbl.pdf\u3009 (Accessed on November 27, 2018)."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104388_bib159","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104388_bib160","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","article-title":"HER2 Overexpression as a poor prognostic determinant in resected biliary tract cancer","volume":"25","author":"Vivaldi","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib161","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104388_bib162","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"de Vries","year":"2023","journal-title":"Cancer Med"},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104388_bib163","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.3390\/cancers14225489","article-title":"Triple Combination of Immune Checkpoint Inhibitors and BRAF\/MEK Inhibitors in BRAF V600 Melanoma: Current Status and Future Perspectives","volume":"14","author":"Welti","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib164","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1476","article-title":"Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma","volume":"6","author":"Xin","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/hbsn.2019.08.05","article-title":"Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice","volume":"8","author":"Xue","year":"2019","journal-title":"Hepatobiliary Surg. Nutr."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104388_bib166","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.trecan.2021.04.003","article-title":"Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy","volume":"7","author":"Yang","year":"2021","journal-title":"Trends Cancer"},{"issue":"24","key":"10.1016\/j.critrevonc.2024.104388_bib167","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152670","article-title":"Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers","volume":"131","author":"Yarchoan","year":"2021","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104388_bib168","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104388_bib169","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/hep.31862","article-title":"Molecular Characterization of biliary tract cancer predicts chemotherapy and programmed death 1\/programmed death-ligand 1 blockade responses","volume":"74","author":"Yoon","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104388_bib170","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/HEP.0000000000000365","article-title":"Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced\/metastatic biliary tract cancers","volume":"78","author":"Yoo","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104388_bib171","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.21037\/jgo-21-776","article-title":"Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma","volume":"12","author":"Zheng","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104388_bib172","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.21037\/atm-20-1007","article-title":"Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report","volume":"8","author":"Zhou","year":"2020","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.critrevonc.2024.104388_bib173","article-title":"Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104388_bib174","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma With IDH1 mutation: the phase 3 randomized clinical claridhy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:07:45Z","timestamp":1718867265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":174,"alternative-id":["S1040842824001318"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104388","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104388"}}